Back to results
US 11,813,318 B2Granted
Beta-2 microglobulin-deficient cells
AssigneeUniversity of Washington
InventorsDavid W. Russell, Roli K. Hirata
Life of this patent
Estimating the term…
Abstract
The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.
Claims16
An isolated human cell comprising
- (a) a genetically engineered disruption of the endogenous beta-2 microglobulin (B2M) gene,
- (b) one or more polynucleotides capable of encoding a single chain fusion non-classical human leukocyte antigen (HLA) class I protein, wherein the single chain fusion non-classical HLA class I protein comprises at least a portion of B2M protein covalently linked to at least a portion of an HLA-E class I α chain;
- wherein the single chain fusion non-classical HLA I protein is capable of normal function with respect to engaging the inhibitory receptors on the surface of NK cells.
Dependencies are inferred from the claim text.